31-08-2011 14:07 Researchers at Penn's Abramson Cancer Center have molecularly engineered T-cells from patients with chronic lymphocytic leukemia and achieved an exceptional, unprecedented antitumor response. In the pilot study of three patients, two achieved complete remission and the third experienced remarkable antitumor response, which was impossible with previously available treatments.
See the original post:
Genetically Modified T Cells Obliterate Chronic Lymphocytic Leukemia Tumors - Video